Menten AI designs peptide and protein therapeutics using quantum…
Company research
Public company, workplace, funding, and market signals
Overview
Menten AI is a San Francisco-based, remote-first biotechnology company that builds MAUD 1.0, a generative-AI platform for de novo design of cyclic peptide macrocycles and other peptide therapeutics, with an emphasis on hard-to-drug targets such as protein-protein interfaces.
Primary product
MAUD 1.0 generative AI platform for de novo cyclic peptide / macrocycle drug design
Founded
2020
Headquarters
San Francisco, California, United States
Team size
10-20
Work style
Remote
Industry
Biotechnology Research
Sub-industry
AI drug discovery / peptide therapeutics
Offices
San Francisco, California, United States
Palo Alto, California, United States
Toronto, Ontario, Canada
Business model
B2B research collaborations
platform licensing
strategic pharma partnerships
Funding
Stage
Seed
Total raised
$4.3M
Latest round
Seed VC - II · Jun 2023
People & investors
Leadership
Co-Founder and CEO
Academic Co-Founder
VP of Business Development / Head of Business Development
Part-Time CFO
Associate Director, Platform Development
Alliances Manager
Associate Director, Protein Design
Founder / Co-Founder
Work & culture
Mission-driven and science-heavy, with explicit emphasis on teamwork, compassion, diversity, resilience, kindness, and a healthy lifestyle rather than office perks.
Work style
Remote
Compensation
Public job copy indicates salary plus equity, along with benefits such as flexible PTO, medical coverage, wellness/fitness allowances, and internet reimbursement.
Benefits
unlimited vacation / flexible PTO
medical coverage
wellness and fitness allowances
internet reimbursement
salary and equity
Product & market
Pricing
Enterprise B2B research collaborations and platform licensing; pricing is not publicly disclosed.
Differentiators
- —de novo design of cyclic peptide macrocycles
- —generative AI combined with physics-based models and quantum simulations
- —physics-informed reinforcement learning instead of reliance on large training datasets
- —validated across the preclinical discovery pipeline
- —focus on oral bioavailability and cell permeability
- —targets hard-to-drug protein-protein interfaces
Technology
Google Cloud Platform
Google Cloud SQL
PostgreSQL
Python
TypeScript
Terraform
CDK for Terraform
GitLab
Jenkins
Docker
Linux
Gromacs
GAMESS
NumPy
Rosetta
C
Customers
Bristol Myers Squibb
top-10 pharmaceutical partners
Scale & contact
Estimated revenue
~$2.1M ARR (public estimate from GetLatka, 2024)
Estimated monthly visits
2.2K
Traffic estimate as of Oct 2025
Jobs and careers at Menten AI
0 jobs at Menten AI
No open positions
Check back later for new openings